ChromaDex board member Jeffery Baxter resigns effective April 4, 2022

Niagen Bioscience, Inc.

Jeffery Baxter resigned from the board and its Audit and Nominating/Governance committees on April 4, 2022.
Resignation not due to any disagreement with the company on operations, policies, or practices.
Company has not announced a replacement at this time.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jeffery Baxter

Director

NAGE · Niagen Bioscience, Inc.

Effective: 2022-04-04
Filed: April 8, 2022, 7:59 PM ET

On April 4, 2022, Jeffery Baxter notified ChromaDex Corporation (the “Company”) of his intention to resign from the board of directors of the Company (the “Board”) and as a member of the Audit Committee and Nominating and Corporate Governance Committee of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeffery Baxter resigned as Director at Niagen Bioscience, Inc..

Action: resigned
Role: Director

Exact text from the filing

On April 4, 2022, Jeffery Baxter notified ChromaDex Corporation (the “Company”) of his intention to resign from the board of directors of the Company (the “Board”) and as a member of the Audit Committee and Nominating and Corporate Governance Committee of the Board.

View on SEC.gov

Niagen Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-008833

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.